Posts tagged Section 505(q)(1)(E).
Blogs
3 minute read
On October 2, 2018, FDA Commissioner Scott Gottlieb released a statement announcing new agency actions to further deter “gaming” of the generic drug approval process through the use of citizen petitions. Among these actions, the most significant was the issuance of a revised draft guidance on citizen petitions subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act (“FDCA”), published on the same day. The stated goal of this revision was to create a more efficient approach to 505(q) petitions and to allow the Agency to focus reviewer resources on scientific ...
Blog Editors
Recent Updates
- Legislative Push for FDA Preemptive Authority Over Dietary Supplement Regulation
- GUARD and GLOBE Pricing Models Could Test Manufacturer Rebates for Medicare Part B and D Drugs
- FDA’s Office of Dietary Supplement Programs Signals Key Enforcement and Policy Priorities for the Year Ahead
- OIG Issues Guidance, Request for Information on DTC Programs
- OIG Greenlights Cost-Sharing Waiver for Commercially Insured Patients